TAK-875 er-5 Wendling T

Wendling T

after treatment of wild-type and p53-deficient MEFs with Danusertib

Cyclo(L-arginylglycyl-L-aspartyl-D-phenylalanyl-N-methyl-L-valyl)

and this is accompanied by 59% inhibition of tumor growth

Antiosteoporotic activity of echinacoside in ovariectomized rats

TAK-875 er-5 Wendling TTAK 875, is a potent, selective, and orally bioavailable GPR40 agonist, with a pharmacokinetic profile enabling long acting drug efficacy. TAK 875 showed potent plasma glucose lowering action and insulinotropic action during an oral glucose tolerance test in female Wistar fatty rats with impaired glucose tolerance. TAK 875 is currently in clinical trials for the treatment of type 2 diabetes mellitus. Product information CAS Number: 1000413 72 8